Rechercher des projets européens

27 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Optimizing a deployable high efficacy malaria vaccine (OptiMalVax)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,

A highly effective malaria vaccine against Plasmodium falciparum should help prevent half a million deaths from malaria each year. New vaccine technologies and antigen discovery approaches now make accelerated design and development of a highly effective multi-antigen multi-stage subunit vaccine feasible. Leading malariologists, vaccine researchers and product developers will here collaborate in ...
Voir le projet

 17

 TERMINÉ 

COllaborative Management Platform for detection and Analyses of (Re-)emerging and foodborne outbreaks in Europe (COMPARE)

Date du début: 1 déc. 2014, Date de fin: 30 nov. 2019,

COMPARE aims to harness the rapid advances in molecular technology to improve identification and mitigation of emerging infectious diseases and foodborne outbreaks. To this purpose COMPARE will establish a “One serves all” analytical framework and data exchange platform that will allow real time analysis and interpretation of sequence-based pathogen data in combination with associated data (e.g. c ...
Voir le projet

 32

 TERMINÉ 

TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,

The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Express ...
Voir le projet

 49

 TERMINÉ 

I-MOVE+ Integrated Monitoring of Vaccines Effects in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly (I-MOVE-plus)

Date du début: 1 mai 2015, Date de fin: 31 oct. 2018,

The I-MOVE+ Consortium includes European Union (EU) Public Health Institutes, SME and Universities. It aims at measuring and comparing the effectiveness (VE) and impact (VI) of influenza and Pneumococcal vaccines and vaccination strategies a in the elderly population in Europe. The goal is to develop a sustainable platform of primary care practices, hospitals and laboratory networks that share val ...
Voir le projet

 33

 TERMINÉ 

Aggression subtyping for improved insight and treatment innovation in psychiatric disorders (AGGRESSOTYPE)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Aggression is a basic physiological trait with important roles throughout evolution, both in defence and predation. When expressed in humans in the wrong context, aggression leads to maladjustment, social impairment and crime. Despite this, knowledge about aggression aetiology is limited and current treatment strategies are insufficient. Contingent to a subdivision into impulsive and instrumental ...
Voir le projet

 27

 TERMINÉ 

Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to rapidly provide robust data on vaccine benefits and risks to support accelerated decision-making.Approach: To achieve this vision through a public-private partnership, ADVANCE partners 1. establish common grounds and rules for collaboration between public and ...
Voir le projet

 30

 TERMINÉ 

Preserving old antibiotics for the future : assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for off-patent antibiotics (AIDA)

Date du début: 1 déc. 2011, Date de fin: 30 nov. 2017,

The AIDA project aims to answer the question of clinical effectiveness and optimal dosing of 5 off-patent antibiotics for infections caused by multiple drug resistant (MDR) bacteria in three randomized controlled clinical trials. In an era of increasing emergence of drug resistance (EDR) and lack of new antibiotics, old off- patent antibiotics are increasingly being prescribed to patients. However ...
Voir le projet

 19

 TERMINÉ 

Long-term effects of early nutrition on later health (EARLYNUTRITION)

Date du début: 1 févr. 2012, Date de fin: 31 oct. 2017,

Nutrition during early development has an important impact on later health, particularly through greater obesity risk, as demonstrated by FP6 EARNEST. EarlyNutrition explores the current key hypotheses on likely causes and pathways to prevention of early life origins of obesity (specifically adiposity) and associated disorders. We bring extraordinary expertise and study populations of 470,000 indi ...
Voir le projet

 40

 TERMINÉ 

Universal Influenza Vaccines Secured (UNISEC)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

UNISEC brings together a European consortium of 3 University partners, 5 National Health Institutes and 3 SMEs, all with leading expertise in influenza vaccine research and development, to work on promising recently developed concepts for a universal influenza vaccine. The consortium is exceptionally strong, interdisciplinary and intersectional in nature, and encompasses a unique combination of sc ...
Voir le projet

 15

 TERMINÉ 

Advanced Immunization Technologies (ADITEC)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2017,

Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and ...
Voir le projet

 53

 TERMINÉ 

Resistance in Gram-Negative Organisms: Studying Intervention Strategies (R-GNOSIS)

Date du début: 1 oct. 2011, Date de fin: 31 mars 2017,

Antibiotics are a mainstay of public health, but their use has increased exponentially leading to the emergence of antibiotic resistance. The R-GNOSIS (Resistance in Gram-Negative Organisms: Studying Intervention Strategies) project combines 5 international clinical studies, all supported by highly innovative microbiology, mathematical modelling and data-management, to determine - in the most rele ...
Voir le projet

 27

 TERMINÉ 

BBMRI - Large Prospective Cohorts (BBMRI-LPC)

Date du début: 1 févr. 2013, Date de fin: 31 janv. 2017,

In recent years, biomedical research has crossed international borders in large, collaborative studies showing the value of multidisciplinarity and scale advantage. This has yielded valuable insights and some led to new and better medicines and treatments for diseases. However, disease-focused studies provide less insight in the real disease onset, the relative disease burden in the population, an ...
Voir le projet

 36

 TERMINÉ 

Biomarkers For Enhanced Vaccine Safety (BIOVACSAFE)

Date du début: 1 mars 2012, Date de fin: 31 déc. 2016,

BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised into focused Activity Cores to generate knowledge and tools to benchmark licensed vaccine reactogenicity, and create practical and generalizable guidelines and techniques to enhance immunosafety of novel vaccines from pre-development to post-marketing surveil ...
Voir le projet

 24

 TERMINÉ 

Optimising the impact and cost-effectiveness of child health intervention programmes of vaccines and micronutrients in low-income countries (optimunise)

Date du début: 1 mars 2011, Date de fin: 31 août 2016,

International child health programmes in low-income countries are justified in term of their impact on child survival. However, the effect estimates are usually calculated from performance indicators and assumptions about efficacy based on small-scale target-specific studies. There is little follow-up of how the programmes are implemented in real life.This approach is clearly not sufficient. Recen ...
Voir le projet

 9

 TERMINÉ 

Comprehensive molecular analysis and differentiation of the eukaryotic microbiota in faecal samples from human cohorts to establish the role of intestinal eukaryotes in health and disease (GUT18S)

Date du début: 1 août 2012, Date de fin: 31 juil. 2016,

...ryotes. This is probably partly due to the fact that a broad 18S strategy – similar to the 16S strategy – involves unwanted amplification of human DNA. However, at the Laboratory of Parasitology, Statens Serum Institut, we have developed an 18S PCR method, which avoids amplification of human DNA. This means that PCR products can be analysed using NGS technology and bioinformatics tools without spe ...
Voir le projet

 1

 TERMINÉ 

Child health intervention interactions in low-income countries (CHILIC)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2014,

Vitamin A supplementation (VAS) and vaccines are the most powerful tools to reduce child mortality in low-income countries. However, we may not use these interventions optimally because we disregard that the interventions may have immunomodulatory effects which differ for boys and girls and which may interact with the effects of other interventions. I have proposed the hypothesis that VAS and vacc ...
Voir le projet

 1

 TERMINÉ 

Clinical development of a Pfs48/45-based malaria transmission blocking vaccine (REDMAL)

Date du début: 1 mars 2010, Date de fin: 30 nov. 2014,

Malaria vaccines are needed to reduce the unacceptably high burden of disease and death in particular in the lowest income countries. Malaria vaccines aim at interruption of the life cycle of the parasite Plasmodium falciparum by induced immune responses in the humans. Transmission-blocking vaccines (TBMV) specifically aim at an arrest sexual stage development preventing the generation of infectio ...
Voir le projet

 6

 TERMINÉ 

European Research Infrastructure on Highly Pathogenic Agents (ERINHA)

Date du début: 1 nov. 2010, Date de fin: 31 août 2014,

In the context of the emerging and re-emerging infectious diseases involving highly pathogenic microorganisms, European countries have to be well-prepared to face such threats. However, the Biosafety Level 4 (BSL4) capacity in Europe is not sufficient enough to cover the efficient development of diagnosis, prophylactic and therapeutics means against these pathogens. Moreover, there is no global co ...
Voir le projet

 27

 TERMINÉ 

Pan-European network for the study and clinical management of drug resistant tuberculosis (TB PAN-NET)

Date du début: 1 janv. 2009, Date de fin: 30 juin 2014,

"This proposal will establish an integrated and synergistic network to address the challenge of multiple drug resistant tuberculosis (MDR-TB) facing the EU. The objective will be attained through the establishment of a European consortium of expert partners with extensive experience in the conduct of basic and clinical research relating to MDR-TB, TB control and epidemiology. This Consortium will ...
Voir le projet

 32

 TERMINÉ 

Discovery and preclinical development of new generation tuberculosis vaccines (NEWTBVAC)

Date du début: 1 janv. 2010, Date de fin: 28 févr. 2014,

"With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current ...
Voir le projet

 39

 TERMINÉ 

Predicting antibiotic resistance (PAR)

Date du début: 1 avr. 2010, Date de fin: 31 mars 2013,

"The aim of this proposal is to describe and predict the dynamics of antibiotic resistance development at the level of the drug target, the microbe and the host. That is, we want to generate the knowledge required to be able to connect resistance mechanism --> bacterial physiology and fitness --> bacterial survival within a host --> bacterial spread between hosts. To achieve this goal we will deve ...
Voir le projet

 12

 TERMINÉ 

The T cell immune response against latent infection with Mycobacterium tuberculosis (TILIM)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2012,

"One third of the world's population is infected with latent TB, which therefore constitutes the largest reservoir for TB. In 5% of latently infected individuals TB will eventually re-activate, and it is believed that most new TB cases is indeed due to re-activation of latent TB. TB is a chronic disease, and during the long interaction with the host, the immune response against TB antigens tend to ...
Voir le projet

 1

 TERMINÉ 

Next Generation HIV-1 Immunogens inducing broadly reactive Neutralising antibodies (NGIN)

Date du début: 1 févr. 2008, Date de fin: 31 juil. 2012,

"The elicitation of broadly neutralising antibodies (Nab) remains the primary and most challenging goal in HIV-1 vaccine development. Although a few anti-HIV-1 monoclonal antibodies with broadly neutralising capability have been isolated from infected individuals, none of the immunization strategies thus far explored has proven effective in inducing similar antibodies. Objective of this applicatio ...
Voir le projet

 18

 TERMINÉ 

Initiative on Optimizing Malaria Vaccine Lab Assays Evaluation (OPTIMALVAC)

Date du début: 1 avr. 2009, Date de fin: 31 mars 2012,

"A broad-range of candidate malaria vaccines derived from diverse novel technologies have resulted from the multiple approaches being taken by different groups in developing malaria vaccines. The majority of the candidates are recombinant proteins based on complex native antigens found on the surface of the parasite. Vaccine potential of these parasite surface antigens is often supported by epidem ...
Voir le projet

 14

 TERMINÉ 

"Optimisation of the development of Poverty-Related-Diseases (PRD) vaccines by a transversal approach, addressing common gaps and challenges." (INYVAX)

Date du début: 1 févr. 2009, Date de fin: 31 janv. 2012,

"A number of new vaccines are being developed against Poverty-Related infectious diseases of major public health importance at a global level. The development of all those vaccines is facing the same kind of challenges and gaps, which still prevent 1) the establishment of readily accessible formulation and scale-up process development capacity for neglected diseases vaccines. 2) the establishment ...
Voir le projet

 10

 TERMINÉ 

Preventing community and nosocomial spread and infection with MRSA ST 398 - instruments for accelerated control and integrated risk management of antimicrobial resistance (PILGRIM)

Date du début: 1 janv. 2009, Date de fin: 31 déc. 2011,

"Methicillin-resistant Staphylococcus aureus (MRSA) are of increasing concern both as community- and hospital-acquired pathogens. Since 2005, a specific clone, MRSA ST398 is spreading both in livestock populations and occupationally-exposed people resulting in human infection and disease in several EU Member States. The key objective of the PILGRIM project is to provide a range of novel control m ...
Voir le projet

 12

 TERMINÉ 

"Establishment, Strategy and Initial activities of the TuBerculosis Vaccine Initiative : Coordination of European efforts with global research initiatives." (ESI-TBVI)

Date du début: 1 mai 2008, Date de fin: 30 avr. 2010,

"The goal is to establish a TB Vaccine Initiative (TBVI) as a private public partnership. It will ensure an appropriate linkage between EC supported projects and global initiatives aiming at the development of new TB vaccines. TBVI will be established as a legal entity stemming from TBVAC, the FP6 EC supported project on TB vaccines, that has proven remarkably successful. TBVI will aim to facilita ...
Voir le projet

 5